Serum Cortisol and DHEA-S Levels in Schizophrenic Patients with Different Response to Antipsychotic Therapy: Association with Psychopathology / Серумски Концентрации На Кортизол И DHEA-S Кал Пациенти Со Шизофренша Со Различен Одговор На Антипсихотичната Терапша Асоци.1Аци.1А Со Психопатологшата
Background: Previous studies suggested that alterations in serum cortisol and DHEA-S levels may play a role in the pathophysiology of schizophrenia. Imbalance in serum cortisol and DHEA-S levels may be related to responsivity to antipsychotic treatment.
Aim: To compare serum cortisol and DHEA-S levels between patients with schizophrenia and healthy controls and to evaluate their association with psychopathology in schizophrenic patients with different response to antipsychotic treatment.
Material and Methods: This clinical prospective study included 60 patients with schizophrenia and 40 healthy age and sex matched controls. All patients experienced an acute exacerbation of the illness (PANSS: P1 and P3 ≥ 4). Clinical evaluation of patients was performed using the Positive and Negative Symptom Scale. A questionnaire for socio-demographic and clinical data collection was used. For the purposes of the study, the examined group was divided in two subgroups: responders and nonresponders. Serum cortisol and DHEA-S levels were measuredat baseline in all participants and after 3 and 6 weeks of the antipsychotic treatment in patients with schizophrenia.
Results: Patients with schizophrenia had significantly higher serum cortisol and DHEA-S levels comparedwith control group. Responders had significantly higher serum cortisol and DHEA-S levels compared with nonresponders. Responders group had significant correlation between serum cortisol and PANSS positive scale score as well as between hostility and serum DHEA-S.
Conclusion: Elevated serum cortisol and DHEA-S levels may play a role in the pathophysiology of schizophrenia. Serum cortisol and DHEA-S are associated with psychopathology in schizophrenic patients with different response to antipsychotic therapy.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Raison CL & Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003; 160: 1554-65.
2. Kaneko M Yokoyama F Hoshino Y et al. Hypothalamicpituitary- adrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiology. 1992; 25: 1-7.
3. Yıldırım O Dogan O Semiz M et al. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin Neurosci. 2011; 65: 584-91.
4. Ryan MC Sharifi N Condren R et al. Evidence of basal pituitary-adrenal overactivity in first episode drug naive patients with schizophrenia. Psychoneuroendocrinology. 2004; 29: 1065-70.cn_2252 584..591
5. Walder DJ Walker EF Lewine RJ. Cognitive functioning cortisol release and symptom severity in patients with schizophrenia. Biol Psychiatry. 2000; 48: 1121-32.
6. Gallagher P Watson S Smith MS et al. Plasma cortisol- dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res. 2007; 90(1-3): 258-65.
7. Zhang XY Zhou DF Cao LY et al. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 2005; 30(8): 1532-8.
8. Yilmaz N Herken H Cicek HK et al. Increased levels of nitric oxide cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract. 2007; 16(2): 137-41.
9. Hori H Teraishi T Sasayama D et al. Elevated cortisol level and cortisol/DHEAS ratio in schizophrenia as revealed by low-dose dexamethasone suppression test. The Open Neuropsychopharmacology. 2012; 5: 18-24.
10. Ritsner M Maayan R Gibel A et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol. 2004; 14: 267-73.
11. Taherianfard M & Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci. 2004; 58(1): 3-9.
12. Morfin R. DHEA and the brain. Taylor and Francis London and New York 2002.
13. Baulieu EE Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol. 1996; 150: S221-S239.
14. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003; 28: 139-68.
15. Oades RD & Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology. 1994; 19(4): 373-85.
16. Strous RD Maayan R Lapidus R et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosteronesulphate in first episode schizophrenia: relationship to gender aggression and symptomatology. Schizophr Res. 2004; 71: 427- 34.
17. Shirayama Y Hashimoto K Suzuki Y et al. Correlation of plasma neurosteroids to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Res. 2002; 58:69-74.
18. Ritsner M Gibel A Ram E et al. Alterations in DHEA metabolism in schizophrenia: Two-month case- control study. Eur Neuropsychopharmacol. 2006; 16: 137-46.
19. Ritsner M Gibel A Maayan R et al. Cortisol/Dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology. 2005; 30: 1913-22.
20. di Michele F Caltagirone C Bonaviri G et al. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res. 2005; 39: 267-73.
21. Garner B Phassuliotis C Phillips LJ et al. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J Psychiatr Res. 2011; 45(2): 249-55.
22. Marx CE Stevens RD Shampine LJ et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006; 31: 1249-63.
23. Shulman Y & Tibbo P. Neuroactive steroids in schizophrenia. Can J Psychiatry. 2005; 50:695-702.
24. Strous RD Maayan R Kotler M et al. Hormonal profile effects following dehidroepiandrosterone (DHEA) administration to schizophrenic patients. Clin Neuropharmacol. 2005; 28: 265-9.
25. Rybakowski J Linka M Matkowski K et al. Dexamethasone suppresion test and the positive and ne gative symptoms of schizophrenia. Psychiatr Pol. 1991; 25:9-15.
26. Tandon R Mazzara C DeQuardo J et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology ventricular enlargement and outcome. Biol Psychiatry. 1991; 29: 953-64.
27. Walker EF Diforio D. Schizophrenia: A neural diathesis- stress model. Psychol Rev. 1997; 104: 667-85.
28. Kay SR Fiszbein A Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-7.
29. Kaneda Y Fujii A Ohmori T. The hypothalamicpituitaryadrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002; 26: 935-8.
30. Newcomer JW Faustman WO Whiteford HA et al. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol Psychiatry. 1991; 29: 855-64.
31. Keshavan MS Brar J Ganguli R et al. DST and schizophrenic symptomatology. Biol Psychiatry. 1989; 26: 847-58.